Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019

Completed

• Conditions: COVID-19; Hemoptysis; Lung TB; Lung Cancer
• Interventions: Procedure: anatomic lung resection

• Registration Number: NCT05513248
• Lead Sponsor: Lung Center of the Philippines

Brief Summary

This study will determine the outcomes of anatomic lung resections in patients who recovered from coronavirus disease 2019 (COVID-19) disease by describing the morbidity and mortality as well as the length of postoperative hospital stay.

Detailed Description

This study will be conducted at the Lung Center of the Philippines. The study design is a retrospective case series implemented via chart review. Online and written patient records will be reviewed to determine the baseline patient characteristics and the preoperative outcomes. Patients who recovered from COVID-19 will be selected from those who underwent anatomic lung resection from June 1, 2020 to May 31, 2022. This study will be done in accordance with the Helsinky Declaration and Good Clinical Practice Guidelines, and will be subject for approval of the institutional Ethics and Technical Review Boards. Descriptive statistics will be used to describe patient characteristics and perioperative outcomes.

Study Timeline

• Study First Submitted: 2022-08-22
• Study First Submitted QC: 2022-08-22
• Study First Posted: 2022-08-24
• Study Start: 2022-10-10
• Primary Completion: 2022-10-31
• Status Verified: 2022-11
• Study Completion: 2022-11-01
• Last Update Submitted: 2022-11-08
• Last Update Posted: 2022-11-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• underwent anatomic lung resection
• previous COVID-19 infection documented by nasopharyngeal swab RT-PCR or GeneXpert
• with negative nasopharyngeal swab RT-PCR or GeneXpert prior to lung resection

Exclusion Criteria

• with incomplete patient records

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients who recovered from COVID-19	anatomic lung resection	patients with previous COVID-19 infection who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy)

Primary Outcome Measures

Name	Time	Method
Major complication rate	perioperative period (up to 30 days after anatomic lung resection)	proportion of patients who develop acute kidney injury, acute myocardial infarction, acute respiratory distress syndrome (ARDS), acute respiratory failure, atelectasis requiring intervention, bronchopleural fistula, empyema thoracis, hemothorax, pneumonia, stroke or venous thromboembolism
Minor complication rate	perioperative period (within 30 days after anatomic lung resection)	proportion of patients who develop atrial fibrillation, pneumothorax or prolonged air leak
Length of postoperative hospital stay	perioperative period (up to 30 days after anatomic lung resection)	time duration from surgery to discharge order
Mortality rate	perioperative period (up to 30 days after anatomic lung resection)	proportion of patients who died due to perioperative complications

Trial Locations

Locations (1)

Lung Center of the Philippines; 🇵🇭 Quezon City, Metro Manila, Philippines